- Home
- TDUP vs RGNX Comparison
TDUP vs RGNX Comparison
Compare TDUP & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- RGNX
- Stock Information
- Founded
- TDUP 2009
- RGNX 2008
- Country
- TDUP United States
- RGNX United States
- Employees
- TDUP N/A
- RGNX N/A
- Industry
- TDUP Catalog/Specialty Distribution
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TDUP Consumer Discretionary
- RGNX Health Care
- Exchange
- TDUP Nasdaq
- RGNX Nasdaq
- Market Cap
- TDUP 368.3M
- RGNX 387.0M
- IPO Year
- TDUP 2021
- RGNX 2015
- Fundamental
- Price
- TDUP $6.37
- RGNX $7.15
- Analyst Decision
- TDUP Buy
- RGNX Strong Buy
- Analyst Count
- TDUP 5
- RGNX 8
- Target Price
- TDUP $5.63
- RGNX $31.75
- AVG Volume (30 Days)
- TDUP 2.9M
- RGNX 1.1M
- Earning Date
- TDUP 05-05-2025
- RGNX 05-12-2025
- Dividend Yield
- TDUP N/A
- RGNX N/A
- EPS Growth
- TDUP N/A
- RGNX N/A
- EPS
- TDUP N/A
- RGNX N/A
- Revenue
- TDUP $266,789,000.00
- RGNX $83,328,000.00
- Revenue This Year
- TDUP $8.43
- RGNX $285.14
- Revenue Next Year
- TDUP $6.58
- RGNX N/A
- P/E Ratio
- TDUP N/A
- RGNX N/A
- Revenue Growth
- TDUP 7.96
- RGNX N/A
- 52 Week Low
- TDUP $0.50
- RGNX $5.04
- 52 Week High
- TDUP $6.56
- RGNX $17.52
- Technical
- Relative Strength Index (RSI)
- TDUP 84.67
- RGNX 43.60
- Support Level
- TDUP $4.19
- RGNX $5.85
- Resistance Level
- TDUP $6.56
- RGNX $10.59
- Average True Range (ATR)
- TDUP 0.39
- RGNX 0.83
- MACD
- TDUP 0.24
- RGNX -0.15
- Stochastic Oscillator
- TDUP 94.26
- RGNX 27.43
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.